Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Sara Frey

Neurology Morgantown, WV Medical Doctor

NPI 1497286058 CMS profile 11911749

1 Medical Center Dr, Morgantown, WV 26506

Open in the dashboard

General payments

$584

27 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Frey of Morgantown, WV is reported in the CMS Open Payments database as having received $584 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $584 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Frey
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sara Frey were reported at $584. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sara Frey Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $584 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program year 2025
  1. AbbVie, Inc. $140 7 payments
  2. Biogen, Inc. $79 4 payments
  3. UCB, Inc. $78 3 payments
  4. SK Life Science, Inc. $76 3 payments
  5. Eisai Inc. $35 2 payments
  6. Novartis Pharmaceuticals Corporation $26 1 payment
  7. Pfizer Inc. $26 1 payment
  8. Merz Pharmaceuticals, LLC $23 1 payment
  9. Lilly USA, LLC $23 1 payment
  10. Neurocrine Biosciences, Inc. $20 1 payment
  11. Other $58 3 payments

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $584 27 payments
Products named General payments · program year 2025
  1. VUMERITY $79 4 payments
  2. TYSABRI $79 4 payments
  3. UBRELVY $69 4 payments
  4. QULIPTA $69 4 payments
  5. BOTOX $49 2 payments
  6. Leqembi $35 2 payments
  7. Zilbrysq $30 1 payment
  8. KESIMPTA $26 1 payment
  9. NURTEC ODT $26 1 payment
  10. ZAVZPRET $26 1 payment
  11. Other $217 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

79

Median for Neurology: 833

Drug cost

$2,317

Median for Neurology: $202,670

Branded share of claims

19%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Galantamine Hbr Generic 16 $1,157
Levetiracetam Generic 19 $590
Topiramate Generic 18 $315
Rizatriptan Rizatriptan Benzoate Brand 15 $185
Donepezil Hcl Generic 11 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$23,702

Medicare's payments for the services billed

Medicare patients

132

Average age 70

Services billed

249

58 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 52%
Diabetes 46%
Depression 45%
COPD 42%
Heart failure 38%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record